Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

Inclusion criteria

• Age 19+
• Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)
• Patients who understand the content of the subject description and voluntarily sign the subject

Exclusion criteria

• Age 86+
• Hemodynamically unstable patient
• Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus, contrast agent
• Patients at high risk of bleeding, anemia, thrombocytopenia
• Patients requiring oral anticoagulants
• Pregnant women or women of childbearing age
• Life expectancy is less than one year
• Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin, napjodone, ritonavir, atazanavir)
• Patients with a history of intracranial hemorrhage
• Patients with moderate to severe hepatic impairment
• Patients underwent coronary intervention with stenting within 1 year
• Patients with left-main lesions requiring coronary intervention
• Patients with chronic stricture lesions requiring treatment
• Patients with in-stent restenosis in a lesion requiring treatment
• Patients with bifurcation lesions requiring stenting in lateral branches
• Patients with lesions requiring more than 3 stents